Reliability and validity of the functional assessment of cancer therapy-ovarian.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Clinical Oncology

• Publication date

  2001-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2001.19.6.1809PMID 11251013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument

  1999cited by this paper
• Palliative Care and Quality of Life Considerations in the Management of Ovarian Cancer

  1998cited by this paper
• Social desirability and the clinical self-report inventory: methodological reconsideration.

  1998cited by this paper
• Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

  1997cited by this paper
• Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale

  1997cited by this paper
• Absorption, social desirability, and symptoms in a behavioral medicine population.

  1997cited by this paper
• Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

  1997cited by this paper
• Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system.

  1997cited by this paper
• Social desirability, perceived stress, and PACT ratings in lung transplant candidates: A preliminary investigation

  1996cited by this paper
• The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy‐head and neck scale: A study of utility and validity

  1996cited by this paper
• The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT‐G) in patients with primary brain tumors

  1995cited by this paper
• The epidemiology of ovarian cancer

  1995cited by this paper
• Quality of life of women with ovarian cancer.

  1995cited by this paper
• Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument.

  1995cited by this paper
• The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress.

  1994cited by this paper
• Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms

  1994cited by this paper
• Symptom prevalence, characteristics and distress in a cancer population

  1994cited by this paper
• The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

  1993cited by this paper
• Applied Multivariate Statistics for the Social Sciences

  1993cited by this paper
• Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials

  1992cited by this paper
• Response artifacts in the measurement of subjective well-being

  1991cited by this paper
• Social desirability in measures of subjective well-being: Age comparisons

  1988cited by this paper
• Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.

  1984cited by this paper
• Development of reliable and valid short forms of the marlowe-crowne social desirability scale

  1982cited by this paper
• The CES-D Scale

  1977cited by this paper
• Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide

  1960cited by this paper
• A new scale of social desirability independent of psychopathology.

  1960cited by this paper

• Feasibility of a mobile health platform for patient education and remote symptom monitoring in patients with advanced ovarian cancer undergoing primary chemotherapy.

  2026cites this paper
• Challenges and opportunities to address the emerging burden of targeted therapies in ovarian cancer

  2025cites this paper
• Efficacy of Maintenance Therapy With Adjuvant Chemotherapy of Three Steps in Patients Newly Diagnosed With Advanced Ovarian Cancer: A Phase II Randomised Clinical Trial

  2025cites this paper
• Health-Related Quality of Life (HRQoL) Assessments in Research on Patients with Adult Rare Solid Cancers: A State-of-the-Art Review

  2025cites this paper
• Hyperthermic Intraperitoneal Chemotherapy (HIPEC) vs. Postoperative Intraperitoneal (IP) Chemotherapy - Impact on Health-Related Quality of Life in Primary Ovarian Cancer Patients after Cytoreductive Surgery

  2024cites this paper
• Quality of life and survivorship in patients with low-grade ovarian cancer.

  2024cites this paper
• Living well: Protocol for a web-based program to improve quality of life in rural and urban ovarian cancer survivors.

  2024cites this paper
• The Effect of Cardiac Rehabilitation on Quality of Life and 6-Minute Walk Test in Breast Cancer Patients During Ongoing Anthracycline Based Therapy

  2024cites this paper
• Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer.

  2024cites this paper
• Sleep characteristics and recurrence in platinum-sensitive ovarian cancer survivors: A prospective cohort study

  2024cites this paper
• First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature

  2024cites this paper
• Pre-post feasibility trial of a telephone-delivered exercise intervention for patients during chemotherapy for recurrent ovarian cancer: the ECHO-R trial protocol

  2024cites this paper
• Incorporating patient-reported outcome measures (PROMs) into a clinical quality registry (CQR) for ovarian cancer: considerations and challenges

  2024cites this paper
• Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer

  2024cites this paper
• The biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients.

  2023cites this paper
• Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue.

  2023cites this paper
• Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial

  2023cites this paper
• Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.

  2023cites this paper
• Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review.

  2023cites this paper
• Analysis of risk factors for negative emotions in perioperative period of ovarian cancer patients and their impact on prognosis

  2023cites this paper
• Psychometrics of patient-reported bother from side effects of treatment single-items in industry-sponsored oncology trials

  2023cites this paper
• Predictors of the 6-min walk test in patients with ovarian cancer

  2023cites this paper
• Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.

  2023cites this paper
• Survivorship Care for Women Living With Ovarian Cancer: Protocol for a Randomized Controlled Trial

  2023cites this paper
• Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer

  2023cites this paper
• The research landscape of the quality of life or psychological impact on gynecological cancer patients: A bibliometric analysis

  2023cites this paper
• What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women.

  2023cites this paper
• Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.

  2023cites this paper
• Validity and Reliability of the Turkish Version of National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18) and Neurotoxicity-4 (NTX-4) for Patients with Advanced Ovarian Cancer

  2023cites this paper
• Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice

  2023cites this paper
• Assessment of quality of life among advanced ovarian cancer patients in a tertiary care hospital in India

  2022cites this paper
• Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

  2022cites this paper
• Establishing an Expert Consensus on Key Indicators of the Quality of Life among Breast Cancer Survivors: A Modified Delphi Study

  2022cites this paper
• Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259)

  2022cites this paper
• Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.

  2022cites this paper
• Utilization of an Electronic Patient-Reported Outcome Platform to Evaluate the Psychosocial and Quality-of-Life Experience Among a Community Sample of Ovarian Cancer Survivors.

  2022cites this paper
• Supervised and Non-Supervised Exercise Programs for the Management of Cancer-Related Fatigue in Women with Breast Cancer: A Systematic Review and Meta-Analysis

  2022cites this paper
• Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study

  2022cites this paper
• Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study

  2022cites this paper
• Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.

  2022cites this paper
• Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial—a study protocol of clinical trial

  2022cites this paper
• Evaluation of numerical rating scale and neuropathic pain symptom inventory pain scores in advanced ovarian carcinoma patients undergoing surgery and first-line chemotherapy

  2022cites this paper
• Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

  2022cites this paper
• Qualitative analysis of gynecologic oncology patients’ experience with treatment holidays

  2021cites this paper
• Chronic difficulties are associated with poorer psychosocial functioning in the first year post‐diagnosis in epithelial ovarian cancer patients

  2021cites this paper
• Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

  2021cites this paper
• Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.

  2021cites this paper
• Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.

  2021cites this paper
• Physical and functional well-being and symptoms of ovarian cancer in women undergoing first-line of chemotherapy: a one-year follow-up

  2021cites this paper
• Chronic diffculties are associated with poorer psychosocial functioning in the frst year post‐diagnosis in epithelial ovarian cancer patients

  2021cites this paper
• Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.

  2021cites this paper
• Acceptability and feasibility of early palliative care among women with advanced epithelial ovarian cancer: A Canadian randomized controlled pilot study.

  2021cites this paper
• Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.

  2021cites this paper
• Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer

  2021cites this paper
• Cross‐sectional study of psychosocial well‐being among lesbian, gay, bisexual, and heterosexual gynecologic cancer survivors

  2021cites this paper
• Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

  2021cites this paper
• Phase I study of low-dose fractionated whole abdominal radiation therapy in combination with weekly paclitaxel for platinum-resistant ovarian cancer (GCGS-01).

  2020cites this paper
• Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.

  2020cites this paper
• Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

  2020cites this paper
• Qvida+: Development of a Clinical Decision Support System

  2020cites this paper
• Efficacy and safety of Yiqi Huoxue Jiedu decoction for the treatment of advanced epithelial ovarian cancer patients: a double-blind ran- domized controlled clinical trial

  2020cites this paper
• Validation of the Mexican-Spanish Version of the EORTC QLQ-OV28 Instrument for the Assessment of Quality of Life in Women with Ovarian Cancer.

  2020cites this paper
• Dyadic coping mediates the effects of attachment on quality of life among couples facing ovarian cancer

  2019cites this paper
• OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors.

  2019cites this paper
• Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN).

  2019influential citation
• Quality Surveys to Compare Chemotherapy-induced Toxicity and Quality of Life between Two Paclitaxel and Carboplatin Regimens for Ovarian Carcinoma

  2019cites this paper
• Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers.

  2019cites this paper
• Quality Surveys to Compare Chemotherapy-induced Toxicity and Quality of Life between Two Paclitaxel and Carboplatin Regimens for Ovarian Carcinoma

  2019cites this paper
• Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.

  2019cites this paper
• Surgical versus medical treatment for ocular surface squamous neoplasia: A quality of life comparison.

  2019cites this paper
• Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer.

  2019cites this paper
• Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

  2019cites this paper
• Effects of Reflexology and Progressive Muscle Relaxation on Pain, Fatigue, and Quality of Life during Chemotherapy in Gynecologic Cancer Patients

  2019cites this paper
• Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.

  2019cites this paper
• Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

  2018cites this paper
• 20 – Palliative Care and Quality of Life

  2018cites this paper
• Internet-Based Group Intervention for Ovarian Cancer Survivors: Feasibility and Preliminary Results

  2018cites this paper
• A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer

  2018cites this paper
• Patient reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies: A pilot study.

  2018cites this paper
• Disparities in health-related quality of life in women undergoing treatment for advanced ovarian cancer: the role of individual-level and contextual social determinants

  2018cites this paper
• Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.

  2018cites this paper
• A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.

  2018cites this paper
• The use of patient-reported outcome tools in Gynecologic Oncology research, clinical practice, and value-based care.

  2018cites this paper
• Handbook of Cancer Survivorship

  2018cites this paper
• Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer

  2018cites this paper
• Quality of life after early enteral feeding versus standard care for proven or suspected advanced 1 epithelial ovarian cancer: results from a randomised trial 2

  2018cites this paper
• Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients.

  2017cites this paper
• Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.

  2017cites this paper
• Clinical Trials in Ovarian Cancer

  2017cites this paper
• Ovarian cancer study dropouts had worse health‐related quality of life and psychosocial symptoms at baseline and over time

  2017cites this paper
• The challenge of measuring intra-individual change in fatigue during cancer treatment

  2017cites this paper
• Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer

  2017influential citation
• Dissertation Abstracts

  2017cites this paper
• Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

  2017cites this paper
• Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.

  2017cites this paper
• Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.

  2017cites this paper
• Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.

  2017cites this paper
• Ovarian cancer survivors’ quality of life: a systematic review

  2016cites this paper
• eHealth and the burden of cancer survivorship.

  2016cites this paper
• Does therapeutic writing help people with long-term conditions? Systematic review, realist synthesis and economic considerations.

  2016cites this paper